24 results about "Mitiromycin" patented technology

The present invention belongs to the field of insect cell culture technology and discloses a method for preparing an Sf9 cell feeder layer. The method mainly comprises two steps: step S1 is subculture of Sf9 cells, in which Sf9 cells are cultured in a suitable culture medium to a suitable cell confluence; step S2 is mitomycin C treatment of the Sf9 cells, in which a specific concentration of mitomycin C is used to treat the subcultured Sf9 cells at a specific time and temperature to inhibit their cell division ability, followed by washing to remove mitomycin C and replacing with fresh culture medium. The feeder layer cells obtained by the present invention can effectively inhibit their own proliferation while maintaining good cell activity and structural integrity. They can survive stably and provide necessary support for the co-culture system. They can be used for the cultivation of insect symbiotic bacteria and other difficult-to-culture insect cells. The method is simple to operate, has mild conditions, and good reproducibility. The prepared feeder layer has a stable effect, providing a powerful tool for related research fields.

In specific embodiments, provided is a material for preventing adhesion of membranes in an ophthalmic surgery for treatment of glaucoma or the like without using mitomycin-C or the like. Particularly provided is such material, which is easy to handle and has no risk of histolysis or infections. In a production method of a preferred embodiment, prepared are: aldehyde-modified dextran (first reactant) having weight-average molecular weight of 10,000-5,000,000 and introduced aldehyde group-per-anhydrous glucose unit (mol / AGU) of 0.4-0.7; and succinic anhydride-added poly-L-lysine (second reactant) having weight-average molecular weight of 1000-100,000 and having residual amino group ratio of 80-99%; then, they are mixed together so that aldehyde group-to-amino group molar ratio becomes 0.9-1.1 and are reacted in presence of water so that polymer concentration becomes 8-20%; and a hydrogel produced by the reaction, or a suspension before gelation, is freeze-dried to produce a porous sheet having a thickness of 0.1-0.8 mm.

A lysogenic phage community, its extraction method and application. The tangential flow technology is used to proportionally isolate bacteria and phage communities from in-situ soil, and single-bacteria communities and single-phage communities are obtained through enrichment and concentration. At the same time, mitomycin C is added to the single-bacteria community for lysogenic induction, and then the tangential flow system is used again for filtration and enrichment to obtain a high-throughput lysogenic phage community. Finally, we obtain single-bacteria communities, bacteria-phage mixed communities, and bacteria-lysogenic phage mixed communities. The phage transplantation technology can promote the participation of indigenous microorganisms in the process of promoting plant growth and development. The transplanted lysogenic phages can participate in the synthesis and metabolism of host plant hormones by optimizing the microbial network structure and injecting auxiliary metabolic genes. This method provides a long-term and environmentally friendly microbial synergistic growth promotion technology for the development of green agriculture in China.

The invention relates to the technical field of medicines, in particular to an enantiomer-atesane type diterpenoid compound as well as a preparation method and an application of the enantiomer-atesane type diterpenoid compound. The enantiomer-atesane diterpenoid compound disclosed by the invention is derived from plants, has anti-tumor activity, has cytotoxicity to human leukemia cells, human liver cancer cells and human cervical cancer cells, and is relatively good in inhibitory activity. Wherein the compound 3 has the best effect, the IC50 values of the compound 3 to three human tumor cells are 7.5 + / -1.2 micromole per liter, 9.8 + / -1.0 micromole per liter and 10.1 + / -0.9 micromole per liter respectively, and the activity of the compound 3 is equivalent to that of a positive control drug mitomycin. Particularly, the compound 3 also has good cytotoxicity to drug-resistant liver cancer cells (Huh7-LR cells), and the IC50 value of the compound 3 is 9.6 + / -1.1 micromole per liter. The compound 3 shows huge potential as a lead compound by virtue of the novel chemical structure and potent cytotoxicity shown in various cell lines.

The invention provides a method for purifying mitomycin C. The method comprises the following steps: step 1, adding a surfactant or / and guanidine hydrochloride into fermentation liquor, and carrying out solid-liquid separation; 2, separating through a chromatographic column to obtain a solution containing mitomycin C; and step 3, obtaining a mitomycin C solid from the mitomycin C solution. According to the method provided by the invention, high-purity mitomycin C can be obtained, the yield is high, and the method is suitable for large-scale industrial production.

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of phosphorylation mutation sites of phosphoglucomutase. The mutation site is obtained by mutating threonine at the 144th site of escherichia coli wild-type phosphoglucomutase into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and tetracycline is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

The invention discloses a mitomycin C drug sensitive marker, a detection reagent and application of the mitomycin C drug sensitive marker, the mitomycin C drug sensitive marker is a mitomycin C drug-resistant marker or / and a mitomycin C sensitive marker, and the mitomycin C drug-resistant marker is one or more of PRODH, ANKRD35, ADAMTSL5, PTPRQ, NOXA1, PRAC1, CRYM, NFIB, SYK or DGAT2; and the mitomycin C sensitive marker is one or more of GABRP (gamma-aminobutyric acid binding protein), PABPC1L (poly (p-aminobutyric acid binding protein 1L) or PODXL2 (peroxidase The mitomycin C drug sensitive marker can be used for predicting the drug effect of mitomycin C. According to the present invention, the expression of the related molecules is detected by sequencing the transcriptome of the tissue of the urothelium carcinoma patient, or by using the PC R, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, such that the clue can be provided for the medication of the mitomycin C and the precise treatment of the bladder cancer.

This invention relates to the use of small molecule compounds that allosterically inhibit ALC1 (CHD1L), particularly two classes of ALC1 (CHD1L) allosteric inhibitors of formulas (I) and (II). When combined with inhibitors of several classes of cancer drugs, namely topoisomerase I, topoisomerase II, ATM, ATR, Wee1, BRD, and MEK, or when combined with mitomycin C, paclitaxel, ionizing radiation, or antibody-drug conjugates having tumor-specific antibodies conjugated to TOP1 inhibitors, the small molecule compounds and the allosteric inhibitors exhibit enhancing, preferably additive, effects in the treatment of proliferative diseases. Furthermore, this invention relates to the ALC1 inhibitor of formula (II), which, when combined with PARP inhibitors (poly(ADP-ribose)-polymerase inhibitors (PARPi)), exhibit synergistic effects in the treatment of pancreatic cancer or fallopian tube cancer. By synergizing with the functions of the aforementioned cancer drugs, the ALC1 inhibitors, particularly those of formulas (I) and (II) that enhance the cancer cell killing properties of the aforementioned cancer drugs, are particularly capable of achieving treatments in which any of the aforementioned inhibitors have already been used as part of standard care.

The invention belongs to the field of molecular biology, and particularly relates to a construction method and application of a phosphoenolpyruvate synthase T419D mutation site. The mutation site is obtained by mutating threonine at the 419th site of phosphoenolpyruvate synthase of an escherichia coli wild type into aspartic acid, the sensitivity of an escherichia coli mutant strain with the mutation site to nalidixic acid, mitomycin C and polymyxin sulfate B is remarkably improved, and the mutation site can be used for improving the sensitivity of bacteria to drugs.

1. The name of the design product: liquid guide box (mitomycin). 2. The use of the design product: medical equipment, used for cotton piece to soak appropriate amount of liquid. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1.

The invention discloses a ZnPc-SFeCO compound as well as a preparation method and application thereof, and discloses a general drug design method taking [2Fe-2S] (CO) 6 as an active center, a drug design strategy based on an interference lysosome arginine-SLC38A9-mTORC1-CCDK2 / 4 / 6 path is established, ZnPc-SFeCO is taken as an example, the ZnPc-SFeCO efficiently catalyzes decomposition of arginine in lysosome so as to inhibit activation of SLC38A9, and the application of the ZnPc-SFeCO compound is promoted. According to the present invention, with the application of the CDK2 / 4 / 6, the collection and the activation of the mTORC1 can be accurately blocked, the CDK2 / 4 / 6 activation retardation cell cycle progress can be inhibited, and the treatment effect superior to the clinical first-line anticancer drug mitomycin (MMC) can be obtained in the in-vivo in-situ non-muscular invasive bladder cancer (NIMBC) model and the tumor recurrence prevention and lifetime prolonging experiment.

The invention relates to the technical field of nano materials, in particular to catechol derivative ligands, gold nanoparticles modified by the catechol derivative ligands and application of the catechol derivative ligands. The catechol derivative modified gold nanoparticles provided by the invention can be used as a biological reducing agent, specifically, the specific value of GSH / GSSG in tumor cells is increased, the specific value of NADPH / NADP + is increased, the content of extracellular H2O2 is reduced, the content of GPx is increased, the content of MDA is reduced, and a reductive stress state is formed, so that the catechol derivative modified gold nanoparticles can be used as the biological reducing agent. In a reductive stress state, not only can the proliferation rate of tumor cells be inhibited, but also the mitomycin C can be activated, and the treatment effect of the mitomycin C on tumors can be improved.

The present invention concerns antibody-conjugate having general structure (2):AB-[(L6)-{Z—(L1)n—(L2)o—(L3)p—(L4)q-D}xx]yy   (2)wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention discloses an intraoperative extracorporeal Schlemm tube positioning method and application of the intraoperative extracorporeal Schlemm tube positioning method in a glaucoma surgery, and the intraoperative extracorporeal Schlemm tube positioning method comprises the steps that a conjunctival flap with a dome as a base is manufactured, a full-thickness bulbar conjunctiva is cut off along the corneal limbus radian through a conjunctival shear, and the cut-off length is 8 + / -2 mm; performing blunt separation by clinging to the sclera surface to form a rectangular sclera area; the method comprises the following steps: manufacturing a superficial sclera flap taking limbus corneae as a substrate, forwards sectioning a sclera to a transparent cornea area, placing a mitomycin cotton piece under the sclera flap, staying for 3 minutes, and flushing; a light ring and a shadow ring are observed to be formed on the whole corneal limbus by means of irradiation of the positioning optical fiber device, and lineation marking is carried out; carrying out 1mm * 2mm deep sclera flap sectioning in the direction from 1mm behind the marking line to the limbus corneae until the limbus corneae is transparent; in the sectioning process, 0.3 mm-0. 5 mm in front of the marking line is the rear edge of the outer path Schlemm tube, the outer wall of the outer path Schlemm tube can be opened by conducting conventional fine sectioning on the outer path Schlemm tube at the position, positioning is accurate, and the surgical success rate can be improved.

The application discloses a molecular imprinting ratio type working electrode for detecting mitomycin C and a preparation method and application thereof, and belongs to the technical field of analysis and detection. The application aims to solve the problem of simple and accurate detection of the content of mitomycin C (MMC). The application adopts a solvothermal reaction to prepare cerium-nickel bimetallic organic framework material, adopts ultrasonic reaction to prepare cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material, and adopts the cerium-nickel bimetallic organic framework / multi-walled carbon nanotube composite material and thionine as a modification material of an electrochemical sensing interface. A molecular imprinting ratio type electrochemical sensor with specific recognition response to a template molecule MMC is prepared on the surface of the modified electrode through an electrochemical polymerization method. The application is applied to the detection of the content of MMC, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

The invention discloses a molecularly imprinted ratio-type working electrode for detecting mitomycin C as well as a preparation method and application of the molecularly imprinted ratio-type working electrode, and belongs to the technical field of analysis and detection. The invention aims to solve the problem that the content of mitomycin C (MMC) can be simply, conveniently and accurately detected. According to the preparation method, a cerium-nickel bimetal organic framework material is prepared through solvothermal reaction, a cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material is prepared through ultrasonic reaction, and the cerium-nickel bimetal organic framework / multi-walled carbon nanotube composite material and thionine are used as modification materials of an electrochemical sensing interface. And preparing the molecular imprinting ratio type electrochemical sensor with specific recognition response to the template molecule MMC on the surface of the modified electrode through an electrochemical polymerization method. The method is applied to MMC content detection, and has the advantages of simple operation, low cost, high sensitivity and good selectivity.

This invention relates to the field of nanomaterials technology, specifically to a catechol derivative ligand and its modified gold nanoparticles and their applications. The catechol derivative-modified gold nanoparticles provided by this invention can act as bioreducing agents, specifically by increasing the GSH / GSSG ratio and NADPH / NADP ratio in tumor cells. + By adjusting the ratio, reducing extracellular H2O2 content, increasing GPx content, and decreasing MDA content, a reducing stress state is formed, thus enabling it to act as a biological reducing agent. Under reducing stress, it can not only inhibit the proliferation rate of tumor cells but also activate mitomycin C, enhancing the therapeutic effect of mitomycin C on tumors.

The invention provides a method for inducing a lyogenic phage based on xanthohumol and application thereof, which are suitable for inducing the lyogenic phage in an escherichia coli host and show a remarkable induction effect. Compared with induction by using 1.5 mu g / ml mitomycin C, the fulvic acid with the final concentration of 1 mu g / ml can induce higher bacteriophage titer; in an in-vivo experiment, a mouse infected with escherichia coli is treated by orally taking xanthohumol, the bacterial load can be remarkably reduced, the phage titer is improved, no obvious toxicity exists, a CCK-8 experiment shows that the survival rate of HepG2 cells given with xanthohumol is remarkably higher than that of HepG2 cells given with mitomycin C group with the same concentration, and xanthohumol shows lower cytotoxicity. The method for inducing the lysogenic bacteriophage based on the xanthohumol is suitable for the fields of bacteriophage therapy, microbiology, microbial ecology and the like, and has a wide application prospect.

A medical device may comprise a body including a mixture of polyvinylpyrrolidone (“PVP”) and mitomycin. The medical device may be in any size or shape such that the medical device may be inserted into living tissue, including, but not limited to, a lacrimal punctal plug and a stent. The mixture of PVP and mitomycin may be coated on a portion of the medical device, contained within a cavity on the medical device, disposed on the surface of the medical device or configured as part of the medical device such that the mixture of PVP and mitomycin can be delivered to tissue.

The present invention relates to the field of pharmaceutical technology, and particularly to a mitomycin lyophilized powder, a low-temperature drying device and method for use after pterygium surgery. The lyophilized powder is prepared from a pre-freeze-drying solution through a freeze-drying process; in the pre-freeze-drying solution by mass, it includes mitomycin C: 0.75 mg / ml - 0.95 mg / ml, mannitol: 1.6 mg / ml - 2 mg / ml, and water for injection: make up to the volume. The mitomycin pre-freeze-drying solution provided by the present invention strictly controls the proportion of the solvent system, improves the solution stability, reduces the reconstitution time, reduces the probability of product solvent residue, has better stability of the finished product, and reduces the safety risk of the product.

The present invention relates to compounds comprising a glycopeptide antibiotic, such as vancomycin, dalbavancin or teicoplanin, or a mitomycin C, one or more antibacterial agents, and a biodegradable linker linking the glycopeptide antibiotic, such as vancomycin, dalbavancin or teicoplanin, or the mitomycin C and the one or more antibacterial agents.

The application provides a preparation method of a mitomycin freeze-dried preparation, the mitomycin freeze-dried preparation and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method of the mitomycin freeze-dried preparation comprises the following steps: mixing mitomycin, mannitol, a pH regulator and water to obtain a liquid medicine containing mitomycin; and sequentially performing pre-freezing, sublimation drying and desorption drying on the liquid medicine containing mitomycin to obtain the mitomycin freeze-dried preparation; wherein the pre-freezing comprises sequentially performing supercooling treatment and temperature reduction crystallization treatment. In the solution preparation stage of the method, the stability of the mitomycin solution is effectively improved by accurately controlling the pH value and the temperature of the solution, and the generation of impurities in the preparation process is inhibited. In the freeze-drying process, by supercooling the liquid medicine first and then rapidly reducing the temperature in the pre-freezing process, the API is crystallized first compared with the mannitol and water, the supercooled liquid medicine is rapidly frozen with the crystallization as a crystal nucleus, and the freeze-dried finished product with very stable quality can be prepared.

The invention provides a pharmaceutical composition for resisting cell proliferation, fibrosis and epithelial-mesenchymal transition and application of the pharmaceutical composition, and belongs to the technical field of biological medicines. According to the invention, mitomycin-C (MMC) and doxorubicin (DOX) are combined for use according to a specific molar ratio, so that proliferation and migration of various visceral organ lesion cells can be effectively inhibited, and meanwhile, the intracellular oxidative stress level is sharply enhanced, so that obvious damage to a mitochondrial structure and breakage of an intracellular DNA chain are caused. The pharmaceutical composition can reduce the use concentration of a single drug, has the characteristics of resisting cell proliferation and fibrosis, and inhibits the occurrence and development of epithelial-mesenchymal transition, thereby having important application potential in the curative effect of clinically treating various eye diseases, cancers and organ fibrosis.